Biofourmis, a Singapore-based digital healthtech company, raised US$5.0m in Series A funding.
Backers included NSI Ventures and Aviva Ventures, the strategic corporate venture arm of international insurer, Aviva plc.
The company intends to use the funds to scale its commercial operations to provide post-acute patient monitoring services and prepare for the commercial launch of its Software as a Service (SaaS) platform, biovitalsTM.
Led by Kuldeep Singh Rajput, Founder & CEO, Biofourmis has developed a health analytics platform called biovitalsTM, which uses Artificial Intelligence (AI) to integrate and analyze continuous physiology data from clinical grade wearables and to detect personalised patterns that can predict a patient’s health deterioration. This AI-empowered continuous monitoring platform alerts medical professionals to intervene days before a critical event.
In addition to the funding, the company has also entered into a collaboration with Mayo Clinic, which would enable it to access de-identified healthcare data from clinical trials and Mayo’s expert medical insights.